Protagonist Therapeutics Reports Q4/FY25 Results, NDA Filings
Analysis based on 7 articles · First reported Feb 25, 2026 · Last updated Feb 25, 2026
The market is impacted by Protagonist Therapeutics' financial results, which show a net loss but also significant pipeline advancements and anticipated regulatory approvals. The potential commercial launches of ICOTYDE and rusfertide, along with the company's strong cash position, suggest future growth for Protagonist Therapeutics and could influence investor sentiment in the biotechnology sector.
Protagonist Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2025, showing a net loss for both periods. Despite the losses, the company highlighted significant progress in its pipeline, including successful Phase 3 outcomes and the submission of New Drug Applications (NDAs) for ICOTYDE and rusfertide to the United States===Food and Drug Administration. Protagonist Therapeutics expects a U.S. regulatory decision for ICOTYDE in 2026 and anticipates exercising its right to opt out of a 50:50 profit and loss sharing arrangement with Takeda Pharmaceutical Company for rusfertide in Q2 2026. The company also announced new wholly-owned development candidates and expanded its discovery programs, projecting a cash runway through at least the end of 2028.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard